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MaBACKGROUND Bicuspid aortic valves are associated with valve dysfunction, ascending aortic aneurysm and dissection.
Management of the ascending aorta at the time of aortic valve replacement (AVR) in these patients is controversial and has
been extrapolated from experience with Marfan syndrome, despite the absence of comparative long-term outcome data.
OBJECTIVES This study sought to assess whether the natural history of thoracic aortopathy after AVR in patients with
bicuspid aortic valve disease is substantially different from that seen in patients with Marfan syndrome.
METHODS In this retrospective comparison, outcomes of 13,205 adults (2,079with bicuspid aortic valves, 73 withMarfan
syndrome, and 11,053 control patientswith acquired aortic valve disease)whounderwent primaryAVRwithout replacement
of the ascending aorta inNewYork State between 1995 and2010were compared. Themedian follow-up timewas6.6 years.
RESULTS The long-term incidence of thoracic aortic dissection was signiﬁcantly higher in patients with Marfan syndrome
(5.5 2.7%) comparedwith thosewithbicuspidvalves (0.550.21%)and control grouppatients (0.410.08%,p<0.001).
Thoracic aortic aneurysms were signiﬁcantly more likely to be diagnosed in late follow-up in patients with Marfan syndrome
(10.8 4.4%) compared with those with bicuspid valves (4.8 0.8%) and control group patients (1.4 0.2%) (p< 0.001).
Patients with Marfan syndrome were signiﬁcantly more likely to undergo thoracic aortic surgery in late follow-up (10.4 
4.3%) compared with those with bicuspid valves (2.5  0.6%) and control group patients (0.50  0.09%) (p< 0.001).
CONCLUSIONS The much higher long-term rates of aortic complications after AVR observed in patients with Marfan
syndrome compared with those with bicuspid aortic valves conﬁrm that operative management of patients with bicuspid
aortic valves should not be extrapolated from Marfan syndrome and support discrete treatment algorithms for these
different clinical entities. (J Am Coll Cardiol 2015;65:2363–9) © 2015 by the American College of Cardiology Foundation.m the *Department of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai, New York, New York; and the
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ABBR EV I A T I ON S
AND ACRONYMS
AVR = aortic valve
replacement
CI = conﬁdence interval
HR = hazard ratio
ICD-9-CM = International
Classiﬁcation of Diseases-Ninth
Revision-Clinical Modiﬁcation
TAA = thoracic aortic aneurysm
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2364T he prevalence of bicuspid aorticvalves in the general populationis approximately 1% (1). Bicuspid
valves degenerate more frequently and
rapidly than trileaﬂet aortic valves, and
recent clinical history data suggest that as
many as 50% of patients with echocardio-
graphic diagnoses of bicuspid aortic valve
eventually require aortic valve replacement
(AVR) (2,3). The incidence of ascending aortic
dissection in patients with bicuspid aorticvalves is estimated to be 8 times higher than that in
the general population (2), but single-center studies
focusing on the long-term risk for dissection after iso-
lated AVR in patients with bicuspid aortic valves have
yielded conﬂicting outcome data (4–8), so the indica-
tions for concomitant intervention on the thoracic
aorta at the time of AVR are controversial (9). Histo-
pathologic similarities between specimens of aneu-
rysms from patients with bicuspid aortic valves and
Marfan syndrome (10,11) have led to the extrapolation
of treatment algorithms for management of the
ascending aorta in bicuspid aortic valve disease
from aggressive guidelines established for the man-
agement of Marfan syndrome (12,13), despite the
lack of supporting comparative clinical outcome
data (14,15). This study was designed to test the hy-
pothesis that the natural history of thoracic aortop-
athy after AVR in patients with bicuspid aortic valve
disease is substantially different from that seen in
patients with Marfan syndrome.SEE PAGE 2370METHODS
STUDY DESIGN. In this retrospective comparison,
long-term outcomes of adult patients with bicuspid
aortic valves, those with Marfan syndrome, and a
control group of patients with acquired aortic valve
disease undergoing primary AVR without concomi-
tant thoracic aortic surgery in New York State
between January 1, 1995, and December 31, 2010,
were compared according to the etiology of aortic
valve disease. Patients were identiﬁed using the
Statewide Planning and Research Cooperative Sys-
tem, an all-payer, administrative database that pro-
spectively collects data on every hospital discharge,
ambulatory surgery, and emergency department visit
in New York State. Patients undergoing AVR were
identiﬁed using International Classiﬁcation of Dis-
eases, Ninth Revision, Clinical Modiﬁcation (ICD-
9-CM) procedure codes 35.21 and 35.22. Patients with
bicuspid valves were identiﬁed using ICD-9-CM code746.4. The prevalence of bicuspid aortic valves in
this cohort was 3.9%, suggesting that it is under-
diagnosed in comparison with clinical registries of
patients undergoing AVR (16,17). Therefore, to more
accurately identify a control group that did not
contain a substantial number of patients with undi-
agnosed bicuspid valve, we selected patients under-
going AVR with diagnoses of chronic rheumatic aortic
valve disease (ICD-9-CM codes 395.0, 395.1, 395.2,
395.9, 396.0, 396.1, 396.2, 396.3, 396.8, and 396.9).
Patients with Marfan syndrome were identiﬁed using
ICD-9-CM code 759.82, from any hospital admission
before or after surgery.
Exclusion criteria were age < 18 years; out-of-state
residence; any history of thoracic aortic aneurysm
(TAA), thoracic aortic dissection, or thoracic aortic
rupture; concomitant thoracic aortic surgery; prior
thoracic aortic surgery; prior coronary artery bypass
grafting; and prior replacement or repair of any valve
(Online Table 1). Patients with the following genetic
syndromes and inﬂammatory diseases associated
with TAA and dissection also were excluded: Turner
syndrome, Ehlers-Danlos syndrome, Shone complex,
Takayasu arteritis, giant cell arteritis, Behçet disease,
and ankylosing spondylitis (Online Table 1). Patients
undergoing concomitant coronary artery bypass
grafting and other valve surgery were not excluded.
Baseline comorbidities were identiﬁed using diag-
nosis codes from the index hospitalization and all
hospitalizations up to 2 years before the index hos-
pitalization (Online Table 2). The Data Protection
Review Board of the New York State Department
of Health, as well as the Program for Protection of
Human Subjects at the Icahn School of Medicine at
Mount Sinai, approved the study. The approval
included a waiver of informed consent.
STUDY ENDPOINTS. The primary outcome measure
was the cumulative incidence of thoracic aortic
dissection (441.01 and 441.03) or rupture (441.1 and
441.6). Abdominal aortic dissection (441.02) or
rupture (441.3) was not included. Secondary outcome
measures included the cumulative incidence of TAA
(441.2 and 441.7) and thoracic aortic surgery (38.34
and 38.45), as well as overall survival. Deaths were
identiﬁed using the Social Security Death Master File
(current as of November 30, 2013) and by searching
all hospital admissions, ambulatory, or emergency
department visits for patient deaths. Patients for
whom no thoracic aortic dissection or rupture, TAA,
or thoracic aortic surgery was found were censored
on December 31, 2012 (the last date of follow-up by
the Statewide Planning and Research Cooperative
System).
TABLE 1 Patient Baseline Characteristics in the Overall Cohort, According to Etiology
Control
(n ¼ 11,053)
Bicuspid
Aortic Valve
(n ¼ 2,079)
Marfan
Syndrome
(n ¼ 73) p Value
Demographics
Age, yrs 69.5  13.0 55.3  14.9 40.1  14.1 <0.001
Men 5,364 (48.5) 1,494 (71.9) 58 (79.5) <0.001
Race <0.001
White (non-Hispanic) 7,997 (72.4) 1,713 (82.4) 46 (63.0)
African American (non-Hispanic) 742 (6.7) 50 (2.4) n #10*
Hispanic 630 (5.7) 102 (4.9) n #10*
Other/unknown 1,684 (15.2) 214 (10.3) 17 (23.3)
Emergent/urgent admission 5,620 (51.1) 747 (36.1) 21 (28.8) <0.001
Comorbidities
Endocarditis 296 (2.7) 87 (4.2) n #10* <0.001
Coagulation/platelet disorders 684 (6.2) 73 (3.5) n #10* <0.001
Hypertension 6,785 (61.4) 1,034 (49.7) 23 (31.5) <0.001
Diabetes mellitus 2,444 (22.1) 270 (13.0) n #10* <0.001
Coronary artery disease 6,285 (56.9) 750 (36.1) 8 (11.0) <0.001
Peripheral vascular disease 586 (5.3) 52 (2.5) 0 (0) <0.001
Cerebrovascular disease 1,048 (9.5) 94 (4.5) n #10* <0.001
Congestive heart failure 6,162 (55.8) 554 (26.7) 14 (19.2) <0.001
Atrial ﬁbrillation 4,172 (37.8) 260 (12.5) 15 (20.6) <0.001
Chronic obstructive pulmonary
disease
2,334 (21.1) 304 (14.6) 12 (16.4) <0.001
Chronic kidney disease 1,210 (11.0) 75 (3.6) n #10* <0.001
Liver disease 416 (3.8) 54 (2.6) n #10* 0.019
Cancer 197 (1.8) 24 (1.2) 0 (0) 0.066
Aortic coarctation n # 10* 17 (0.8) 0 (0) <0.001
Surgical details
Type of aortic valve prosthesis <0.001
Bioprosthetic valve 5,874 (53.1) 1,154 (55.0) 16 (21.9)
Mechanical valve 5,179 (46.9) 925 (44.5) 57 (78.1)
Concomitant coronary artery
bypass grafting
4,339 (39.3) 436 (21.0) n #10* <0.001
Concomitant other valve surgery 5,205 (47.1) 147 (7.1) 17 (23.3) <0.001
Values are mean  SD or n (%). *One condition imposed by the Statewide Planning and Research Cooperative
System for access to its data is the undertaking not to publish patient data when the number of patients affected
was 10 or less, in order to preserve patient conﬁdentiality.
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2365STATISTICAL ANALYSIS. Continuous variables are
reported as means with standard deviations. Cate-
gorical variables are expressed as proportions.
Assessment of differences in baseline characteristics
and comorbidities among patients in each of the 3
cohorts was performed using analysis of variance for
normally distributed continuous variables and Pear-
son’s chi-square test for categorical variables.
The primary endpoint was assessed using com-
peting risk analysis: cumulative incidence function
curves were constructed for all 3 groups and compared
using Gray’s test. Cox proportional hazards regression
was performed with all baseline characteristics and
comorbidities entered as covariates. Multiple pairwise
competing risk and Cox regression analyses were then
repeated for this endpoint. A similar analysis was
performed for the secondary endpoints of new for-
mation of TAA, as well as thoracic aortic surgery. Sur-
vival was analyzed using the Kaplan-Meier method
and the log-rank test. The proportional hazards
assumption was valid in all Cox models, and for all
models covariates were entered via stepwise selection
(with alpha levels of 0.25 for entry and 0.15 for reten-
tion; see Online Table 3 for variables tested). A sup-
plemental analysis was performedwith the addition of
a fourth group consisting of AVR patientswhowere not
diagnosed with bicuspid valves, Marfan syndrome, or
rheumatic valve disease; this group was likely
composed of true nonbicuspid and undiagnosed
bicuspid valve patients. Analysis of all endpoints was
repeated using themethodology described earlier, and
results are presented in Online Table 4 and Online
Figures 1 to 3. All tests were 2 tailed, and an alpha
level of 0.05 was considered statistically signiﬁcant.
All statistical analyses were performed using SAS
version 9.4 (SAS Institute Inc., Cary, North Carolina).
RESULTS
STUDY POPULATION. A total of 71,134 adults $18 years
of age who underwent primary aortic valve interven-
tion in New York State from January 1, 1995, to
December 31, 2010, were identiﬁed. Patients with 1 or
more of the following criteria were excluded: out-of-
state residence (8.9% [n ¼ 6,303]), any history of TAA
(7.7% [n ¼ 5,439]), thoracic aortic dissection or rupture
(2.1% [n ¼ 1,465]), other genetic syndromes (Turner
syndrome, Ehlers-Danlos syndrome, Shone complex)
(0.1% [n ¼ 46]), inﬂammatory diseases (Takayasu
arteritis, giant cell arteritis, Behçet disease, anky-
losing spondylitis) (0.4% [n ¼ 251]), concomitant
thoracic aortic surgery (7.5% [n ¼ 5,348]), prior
thoracic aortic surgery (0.001% [n ¼ 109]), prior coro-
nary artery bypass grafting (2.9% [n ¼ 2,028]), or priorreplacement or repair of any valve (3.3% [n ¼ 2,320]).
After applying exclusion criteria, 53,990 patients re-
mained: 2,079 patients with bicuspid aortic valves,
73 with diagnoses of Marfan syndrome (14% of whom
were diagnosed as having Marfan syndrome subse-
quent to the index admission), and 51,838 patients
with neither bicuspid valves nor Marfan syndrome.
The majority of patients with Marfan syndrome
(n ¼ 315) were excluded, because they underwent
concomitant thoracic aortic procedures. Of the 51,838
patients, 11,053 were diagnosed with chronic rheu-
matic aortic valve disease, and these subjects formed
the control cohort, representing patients with non-
bicuspid, non-Marfan valves. The median follow-up
time was 6.6 years (range: 0 to 18.9 years).
PATIENT CHARACTERISTICS. Patient baseline demo-
graphic, comorbidity, and surgical details are shown
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2366in Table 1. The mean ages of patients with bicuspid
valves (55.3  14.9 years) and Marfan syndrome
(40.1  14.1 years) were lower than the mean age
of control patients (69.5  13.0 years) (p < 0.001).
The proportion of men was higher in the bicuspid
valve and Marfan syndrome groups (71.9% and 79.5%,
respectively) compared with the control group
(48.5%) (p < 0.001). Patients with bicuspid aortic
valves were more likely to present with endocarditis
(4.2%) compared with those with Marfan syndrome
and the control group (both 2.7%) (p < 0.001). Along
with older age, patients in the control group generally
carried a signiﬁcantly higher burden of comorbid
diseases compared with those with bicuspid valves
and those with Marfan syndrome.
MORTALITY. The control group of patients had
higher 30-day mortality from index AVR (6.2%) than
patients with bicuspid valves (1.5%) and those with
Marfan syndrome (2.7%) (p < 0.001). The unadjusted
15-year survival rate was worse in the control group
patients (38.5  0.6%) compared with patients with
bicuspid valves (72.4  1.5%) and those with Marfan
syndrome (77.0  5.4%) (p < 0.001).
THORACIC AORTIC DISSECTION. At 15 years, the
cumulative incidence of thoracic aortic dissection
was signiﬁcantly higher in patients with Marfanive Incidence of Thoracic Aortic Dissection After AVR,
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ulative incidence of thoracic aortic dissection was signiﬁcantly higher
fan syndrome (5.5  2.7%) compared with those with bicuspid aortic
 0.21%) and control patients with acquired aortic valve disease
e) (0.41  0.08%) (p < 0.001). AVR ¼ aortic valve replacement.syndrome (5.5  2.7%) compared with those with
bicuspid valves (0.55  0.21%) and control group
patients (0.41  0.08%) (p < 0.001) (Figure 1). Multi-
variate Cox regression analysis demonstrated that
patients with Marfan syndrome experienced a sig-
niﬁcantly higher incidence of aortic dissection com-
pared with control patients (hazard ratio [HR]:
15.90; 95% conﬁdence interval [CI]: 6.40 to 39.48;
p < 0.001), whereas the long-term rate of aortic
dissection in patients with bicuspid aortic valves was
not signiﬁcantly different from that seen in control
patients (HR: 1.45; 95% CI: 0.69 to 3.02; p ¼ 0.33). In
pairwise analysis, patients with Marfan syndrome
had a higher incidence of thoracic aortic dissection
than those with bicuspid valves (HR: 13.9; 95% CI:
4.03 to 48.07; p < 0.001). The mean age of patients
with Marfan syndrome at the time of dissection
(46.4  16.8 years) was younger than that of patients
with bicuspid valves (61.6  10.4 years) and control
group patients (73.6  8.7 years) (p < 0.001). A total of
44 thoracic aortic dissections were observed during
follow-up. The 30-day mortality after thoracic aortic
dissection was 72.3%.
TAA. TAAs were signiﬁcantly more likely to be diag-
nosed in late follow-up in patients with Marfan syn-
drome (10.8  4.4%) compared with those with
bicuspid valves (4.8  0.8%) and control group
patients (1.4  0.2%) (p < 0.001) (Central Illustration).
Multivariate Cox regression analysis demonstrated
that bicuspid aortic valves were associated with a
signiﬁcantly higher incidence of TAA compared
with control patients (HR: 1.93; 95% CI: 1.36 to 2.75;
p < 0.001). Marfan syndrome was associated with
higher incidence of new TAA compared with both
control patients (HR: 5.04; 95% CI: 2.19 to 11.61;
p < 0.001) and those with bicuspid aortic valves
(HR: 2.55; 95% CI: 1.07 to 6.08; p ¼ 0.035).
THORACIC AORTIC SURGERY. The cumulative in-
cidence of thoracic aortic surgery at 15 years was
0.50  0.09% for the control group, 2.5  0.6% for the
bicuspid valve group, and 10.4  4.3% for the Marfan
syndrome group (p < 0.001) (Figure 2). Multivariate
Cox regression analysis demonstrated that the inci-
dence of thoracic aortic surgery was much higher in
patients with Marfan syndrome (HR: 11.98; 95% CI:
4.99 to 28.79; p < 0.001) and in those with bicuspid
valves (HR: 2.34; 95% CI: 1.37 to 4.02; p ¼ 0.002)
compared with the control group of patients. In
pairwise analysis, patients with Marfan syndrome
had a higher incidence of thoracic aortic surgery
than those with bicuspid valves (HR: 4.78; 95% CI:
1.86 to 12.30; p ¼ 0.0012). A total of 65 thoracic aortic
surgical procedures were observed during follow-up.
CENTRAL ILLUSTRATION Cumulative Incidence of TAA After AVR,
According to Etiology
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The incidence of new thoracic aortic aneurysm (TAA) formation was signiﬁcantly higher in
patients with Marfan syndrome and those with bicuspid aortic valves (BAVs) compared
with the control group of patients with acquired aortic valve disease (p < 0.001 for both);
additionally, patients with Marfan syndrome had a higher incidence of new TAA formation
compared with those with BAVs (p ¼ 0.035). The much higher long-term rates of aortic
complications after aortic valve replacement (AVR) observed in patients with Marfan syn-
drome comparedwith thosewith BAVs conﬁrms that operativemanagement of patients with
BAVs should not be extrapolated from Marfan syndrome and supports discrete treatment
algorithms for these different clinical entities. TAV ¼ tricuspid aortic valve (control group).
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2367The indication for surgery was thoracic aortic
dissection in 30.8% of cases (n ¼ 20; 37.9% in the
control group, 13.6% in the bicuspid valve group, and
50% in the Marfan syndrome group). The 30-day
mortality rate after thoracic aortic surgery was
10.8%; the 30-day mortality rate after thoracic aortic
surgery for thoracic aortic dissection was 30.0%.
DISCUSSION
In this analysis of a statewide database capturing all
admissions to hospitals in New York State, we ob-
served substantial differences in the long-term out-
comes of patients with Marfan syndrome compared
with those with bicuspid valves after AVR. The “non-
evidence based extrapolation of Marfan syndrome
guidelines” (15) to management of the ascending
aorta in patients with bicuspid aortic valve has pre-
viously been questioned (14,15,18–20); our data pro-
vide additional support for discrete treatment
algorithms for patients with bicuspid valve disease.
LONG-TERM RISK FOR AORTIC DISSECTION. Current
recommendations for aortic resection at the time of
bicuspid AVR vary widely, from liberal replacement
of the ascending aorta regardless of aortic size in any
patient with bicuspid valve disease (8) to selective
approaches based on aortic size with aggressive
(5,7,12,13,21) or more conservative (4,6,22,23) thresh-
olds. This variation in approach is a consequence of
uncertainty regarding the long-term incremental risk
posed to patients with bicuspid valves by aortic
dissection. In single-center studies, the reported
incidence of aortic dissection has ranged from 0% to
10% (4–8); the wide range is due primarily to differ-
ences in surgical strategy and the completeness of
clinical follow-up. In the absence of deﬁnitive long-
term outcome data, consensus guidelines have com-
bined recommendations for the surgical management
of patients with bicuspid aortic valve disease with
those for patients with Marfan syndrome (12,13), in
whom the beneﬁt of aggressive aortic resection in
reducing subsequent risk for aortic dissection is
clearly established. However, our study provides
comparative data that highlight the signiﬁcant dif-
ferences in long-term outcomes between these 2 very
different clinical entities. We found that patients with
Marfan syndrome were 14 times more likely to pre-
sent to the hospital with aortic dissection in long-
term follow-up than patients with bicuspid aortic
valve disease, almost 5 times more likely to undergo
thoracic aortic surgery, and more than twice as
likely to receive a new diagnosis of TAA during
long-term follow-up. These data are consistent with
the ﬁndings of an echocardiographic comparison of50 patients with Marfan syndrome and 353 patients
with bicuspid aortic valves, in which the investigators
found that almost one-half of patients with bicuspid
aortic valves were “nonprogressors,” whereas the
majority of patients with Marfan syndrome experi-
enced progression in aortic dilation over a 2-year
period of follow-up (18).
CLINICAL IMPLICATIONS. Our data suggest that pa-
tients with bicuspid aortic valves undergoing AVR in
the absence of an aneurysmal ascending aorta have
twice the risk for aortic aneurysm formation as non-
bicuspid patients, and are twice as likely to undergo
thoracic aortic resection in long-term follow-up, but
the absolute rates of these complications are low
(<5% cumulative incidence in 15-year follow-up).
The heterogeneous morphology of bicuspid aortic
valve disease and related variation in the pathologic
and clinical course of bicuspid valve aortopathy
are well described (4,18,24–27) and suggest that an
FIGURE 2 Cumulative Incidence of Thoracic Aortic Surgery After AVR,
According to Etiology
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The incidence of subsequent thoracic aortic surgery was signiﬁcantly higher in patients
with Marfan syndrome and those with bicuspid aortic valves (BAVs) compared with the
control group of patients with acquired aortic valve disease (p < 0.001 and p ¼ 0.002,
respectively); additionally, patients with Marfan syndrome had a higher incidence of
thoracic aortic surgery in late follow-up compared with those with BAVs (p ¼ 0.0012).
AVR ¼ aortic valve replacement.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: After
AVR, patients with Marfan syndrome face substan-
tially higher long-term risks for thoracic aortic
dissection, new TAAs, and need for thoracic aortic
surgery compared with patients with bicuspid aortic
valves.
COMPETENCY IN PATIENT CARE: A liberal
approach to aortic resection extrapolated from expe-
rience in Marfan syndrome exposes the majority of
bicuspid aortic valve patients to incremental operative
risk without clear evidence of long-term beneﬁt.
TRANSLATIONAL OUTLOOK: Larger studies
that include serial measurements of aortic diameter are
needed to identify subgroups of patients with bicuspid
aortic valves and related valve morphology and/or
valve dysfunctionwho beneﬁt from replacement of the
aortic root and ascending aorta with or without AVR.
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2368individualized approach focused on identifying high-
risk subgroups of patients with bicuspid aortic valve
disease at the time of AVR most likely to beneﬁt
from concomitant resection of the nonaneurysmal
ascending aorta is warranted. Our data suggest that a
liberal approach to aortic resection extrapolated from
experience in Marfan syndrome exposes the majority
of patients with bicuspid valve to incremental oper-
ative risk without clear evidence of long-term beneﬁt.
STUDY LIMITATIONS. The lack of serial quantitative
data on aortic dimensions was the main limitation of
this study, which prevented us from adjusting for
aortic size at presentation; therefore, we excluded
all patients with documented TAA at baseline.
Second, a small minority of patients with Marfan
syndrome undergo isolated AVR (28), which meant
that the majority of patients with Marfan syndrome in
our cohort were excluded, because they underwent
concomitant resection of the thoracic aorta.
Third, although the use of a statewide rather than a
single-center database improved our ability to detect
dissections, we could not identify patients with
thoracic aortic dissections who did not reach hospi-
tals or determine when patients were hospitalized out
of state, potentially causing us to underestimate therates of dissection and aneurysm formation, although
this would likely have affected all 3 patient groups
equally.
Additionally, the control group in our study may
have included patients with undiagnosed bicuspid
valve; we believe that we were able to minimize this
by excluding patients without rheumatic valve dis-
ease from the control group.
Finally, the Statewide Planning and Research
Cooperative System dataset contains incomplete in-
formation on variables including valve dysfunction,
cusp fusion type, and bicuspid valve aortopathy
phenotypes, which have been reported to inﬂuence
the course of aortopathy (24–27).
CONCLUSIONS
The long-term risk for thoracic aortic dissection in
patients with bicuspid valve after isolated AVR is very
low. The much higher rates of thoracic aortic dissec-
tion, aneurysm formation, and aortic surgery that
were observed in long-term follow-up of patients
with Marfan syndrome after AVR, compared with
those with bicuspid valve, support discrete treatment
algorithms for these different clinical entities.
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